Retatrutide: what the research says
Also known as LY3437943, "triple G" agonist.
In trials Retatrutide is being tested in people and not approved as a medicine.
Key facts
- Class
- An experimental drug that acts on three hormone receptors: GLP-1, GIP and glucagon.
- Phase 2 result
- In a 2023 Phase 2 trial, adults with obesity lost up to 24.2% of body weight on average at 48 weeks.
- Phase 3 status
- Eli Lilly reported Phase 3 (TRIUMPH) results in 2026 and plans to apply to the FDA in 2027. It is not approved anywhere yet.
- The glucagon part
- In animals, glucagon action raised energy use. In people, studies show large drops in liver fat, but whether energy use rises in humans is still being studied.
Anti-doping (WADA) status
Prohibited in sport at all times. Unapproved drugs like retatrutide fall under WADA's S0 non-approved substances rule, in and out of competition.
Status in Nepal
Not approved as a medicine anywhere, so it is not expected to be registered with Nepal's Department of Drug Administration (DDA). Under Nepal's Drugs Act 2035, drugs must be registered before they are imported or sold.
Sources
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (NEJM 2023)
- Eli Lilly: retatrutide Phase 3 TRIUMPH-2 and TRIUMPH-3 results (July 2026)
- Coskun et al., LY3437943, a novel triple agonist (Cell Metabolism 2022, preclinical)
This page explains research. It is not a recommendation to use Retatrutide. Talk to a doctor before using any medicine.